IITRI is happy to share the good news from our collaboration with the National Cancer Institute (NCI) on their program focusing on an inhaled drug against SARS-CoV-2. Our team here at IITRI was contracted to perform toxicology studies for their drug candidate APN-01 administered by nebulizer in dogs. The NCI team has received the NIH Director’s Award for this work which has accomplished going from concept to clinical trial in 18 months. Read more about IITRI’s collaboration with NCI for APN-01 in PLOS ONE and on the Illinois Tech (IIT) website.
Here at IITRI, we look forward to continuing to work with our Sponsors and government partners in the fight against COVID-19 and other emerging pathogens.